NDA 018332 · Cosette
Indocin
Indomethacin · Oral · Nonsteroidal Anti-inflammatory Drug
Last checked: Nov 19, 2026Latest source record: Nov 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1985
Oct 10, 1985
Approved uses
1
Original approval plus efficacy supplements
Registered trials
557
100 Phase 3, 44 recruiting
FAERS reports
13,296
10,490 serious, 1,529 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [ see Warnings and Precautions ( 5.1 ) ]. INDOCIN is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [ see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 ) ]. Gastrointestinal Bleeding, Ulceration, and Perforation NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients...
What it is approved for
From the label in effect Dec 16, 2024.
INDOCIN Oral Suspension is indicated for: Moderate to severe rheumatoid arthritis including acute flares of chronic disease Moderate to severe ankylosing spondylitis Moderate to severe osteoarthritis Acute painful shoulder (bursitis and/or tendinitis) Acute gouty arthritis INDOCIN is a nonsteroidal anti-inflammatory drug indicated for: Moderate to severe rheumatoid arthritis including acute flares of chronic disease Moderate to severe ankylosing spondylitis Moderate to severe osteoarthritis Acute painful shoulder (bursitis and/or tendinitis) Acute gouty arthritis ( 1 )
Mechanism: Indomethacin has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of INDOCIN, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Indomethacin is a potent inhibitor of prostaglandin synthesis in vitro. Indomethacin concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because indomethacin is an inhibitor of prostaglandin...
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 10, 1985 Original approval · Type 3 - New Dosage Form
1 products under this application
- INDOCIN · INDOMETHACIN 25MG/5ML · SUSPENSION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Indomethacin" as an intervention, any sponsor and status, largest first.
- Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP PancreatitisPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT05252754 · 4,874 participants (planned) · Start Jan 18, 2023 · Primary completion Dec 2026
Drug: Tacrolimus capsule; Placebo and 1 more · For: Post-ERCP Acute Pancreatitis
Sites: Baltimore, Maryland; Hyderabad, India; Kolkata, India · 5 sites in all
- Indomethacin vs Diclofenac for Preventing PEPPivotal-lookingRecruiting
Air Force Military Medical University, ChinaAcademic, hospital or other
NCT07071441 · 4,050 participants (planned) · Start Jun 1, 2025 · Primary completion Dec 31, 2026
Drug: Indomethacin 100 MG; Diclofenac 100mg · For: ERCP; Pancreatitis; Non-steroidal Anti-inflammatory (NSAID) and 2 more
Sites: Beijing, China; Chongqing, China; Xiamen, China · 20 sites in all
- Effect of Papillary Epinephrine Spraying on Post-ERCP Pancreatitis in Patients Received Rectal IndomethacinPivotal-lookingTerminated
Air Force Military Medical University, ChinaAcademic, hospital or other
NCT03057769 · 3,300 participants · Start Feb 1, 2017 · Primary completion Oct 26, 2017
Drug: Papillary epinephrine spraying; Papillary saline spraying and 1 more · For: Pancreatitis; Endoscopic Retrograde Cholangiopancreatography
Sites: Xiamen, China; Lanzhou, China; Ankang, China · 10 sites in all
- Rectal Indomethacin Versus Rectal Indomethacin and Sublingual Nitrate for PEP PreventionPivotal-lookingStatus unknown
Air Force Military Medical University, ChinaAcademic, hospital or other
NCT04425993 · 2,700 participants · Start Jul 1, 2020 · Primary completion May 30, 2022
Drug: Isosorbide Dinitrate 5 MG; Indomethacin 100 MG and 2 more · For: Post-ERCP Acute Pancreatitis
Sites: Xiamen, China; Lanzhou, China; Xi'an, China · 4 sites in all
- Oral Resveratrol to Prevent Post-ERCP PancreatitisPivotal-lookingStatus unknown
First Affiliated Hospital Xi'an Jiaotong UniversityAcademic, hospital or other
NCT02947932 · 2,700 participants (planned) · Start Dec 2016 · Primary completion Mar 2018
Drug: Resveratrol; Indomethacin · For: Pancreatitis, Acute; Gastrointestinal Disease
- COX-2 Inhibitor to Prevent Post-ERCP PancreatitisPivotal-lookingStatus unknown
First Affiliated Hospital Xi'an Jiaotong UniversityAcademic, hospital or other
NCT02964403 · 2,700 participants (planned) · Start Dec 2016 · Primary completion Feb 2018
Drug: Cox-2; Indomethacin · For: Pancreatitis, Acute
- Rectal Indomethacin to Prevent Post-ERCP PancreatitisPivotal-lookingCompleted
Air Force Military Medical University, ChinaAcademic, hospital or other
NCT02002650 · 2,600 participants · Start Dec 2013 · Primary completion Nov 2015
Drug: Pre-ERCP rectal Indomethacin; Post-operational Rectal Indomethacin · For: Post-ERCP Acute Pancreatitis
Sites: Lanzhou, China; Yinchuan, China; Xi'an, China · 6 sites in all
- Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP PancreatitisPivotal-lookingRecruiting
Chinese University of Hong KongAcademic, hospital or other
NCT03713879 · 1,734 participants (planned) · Start Mar 21, 2019 · Primary completion May 31, 2028
Drug: Indomethacin · For: Post ERCP Pancreatitis
Sites: Xi'an, China; Shanghai, China; Tianjin, China · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,432
- fatigue1,151
- headache1,058
- arthralgia1,036
- off label use1,027
- nausea949
- pain944
- diarrhoea906
- dizziness894
- dyspnoea770
- vomiting760
- asthenia658
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 358 |
| 2005 | 372 |
| 2006 | 391 |
| 2007 | 385 |
| 2008 | 356 |
| 2009 | 408 |
| 2010 | 374 |
| 2011 | 486 |
| 2012 | 702 |
| 2013 | 430 |
| 2014 | 395 |
| 2015 | 555 |
| 2016 | 681 |
| 2017 | 592 |
| 2018 | 740 |
| 2019 | 820 |
| 2020 | 640 |
| 2021 | 755 |
| 2022 | 1,010 |
| 2023 | 867 |
| 2024 | 884 |
| 2025 | 742 |
| 2026 | 352 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Indocin* (Indomethacin)
2024 spending
$527K
Beneficiaries
28
68 claims
Per beneficiary
$18,812
$225.42 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,157,154 |
| 2021 | $1,727,497 |
| 2022 | $1,840,708 |
| 2023 | $1,458,672 |
| 2024 | $526,749 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis.
Mitra S, Florez ID, Tamayo ME, et al. · JAMA 2018 · Comparative Study, Systematic Review
- Rectal Indomethacin in Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: An Updated Meta-Analysis with Trial Sequential Analysis.
Sawaf B, Najah Q, Almoshantaf MB, et al. · Dig Dis 2025 · Meta-Analysis, Systematic Review
- Indomethacin with or without prophylactic pancreatic stent placement to prevent pancreatitis after ERCP: a randomised non-inferiority trial.
Elmunzer BJ, Foster LD, Serrano J, et al. · Lancet 2024 · Randomized Controlled Trial, Equivalence Trial
- Indomethacin and diclofenac in the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis of prospective controlled trials.
Patai Á, Solymosi N, Mohácsi L, et al. · Gastrointest Endosc 2017 · Meta-Analysis, Systematic Review
- How to select patients and timing for rectal indomethacin to prevent post-ERCP pancreatitis: a systematic review and meta-analysis.
Wan J, Ren Y, Zhu Z, et al. · BMC Gastroenterol 2017 · Meta-Analysis, Systematic Review
- Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.
Ohlsson A, Walia R, Shah SS · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Cosette
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.